Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (Q56899396)
article by Richard E Royal et al published October 2010 in Journal of Immunotherapy
Language:
(P31) (Q13442814)
(P50) (Q2347448)
(Q91337301)
(P304) 828-33
(P407) (Q1860)
(P433) 8
(P478) 33
(P577) +2010-10-00T00:00:00Z
(P921) (Q42824440)
(Q356033)
(Q18556189)
(Q19000961)
(P953) https://europepmc.org/articles/pmc7322622?pdf=render
https://europepmc.org/articles/PMC7322622
https://europepmc.org/articles/PMC7322622?pdf=render
https://doi.org/10.1097/cji.0b013e3181eec14c
https://journals.lww.com/10.1097/CJI.0b013e3181eec14c
(P1433) (Q15763946)
(P1476) "Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma" (language: en)
"Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma" (language: en)
(P2093) Catherine Levy
Keli Turner
Marybeth Hughes
Israel Lowy
Richard E. Royal
Udai S. Kammula
Richard M. Sherry
Suzanne L. Topalian
James C. Yang
Steven A. Rosenberg
(P2860) (Q29619885)
(Q29619344)
(Q34546440)
(Q70655757)
(Q36363721)
(Q46328355)
(Q37460990)
(Q34617610)
(Q38391782)
(Q34602771)
(Q40262911)
(Q56901322)
(Q51104355)
(Q33499384)
(Q36412657)
(Q46043763)
(Q24548229)
(Q34567635)
(Q70937645)
(Q28141319)
(Q36299657)
(Q34695255)
(Q35012602)
(Q24652592)
(Q34657638)
(Q34506417)
(Q46825564)
(Q44125609)
(Q39960994)
(Q81540982)
(Q40573058)
(Q40840410)
(Q77317862)
(Q35901490)
(Q44874671)
(Q34720087)
(Q80765497)
(Q29547565)
(Q81381605)
(Q33961798)
(Q24644442)
(Q37008577)
(Q36286133)
other details
description article by Richard E Royal et al published October 2010 in Journal of Immunotherapy

External Links